ClinicalTrials.gg
CompletedNCT01888393Updated Nov 19, 2013

Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Subjects

A Phase 1 interventional study of lumacaftor 200 mg q12h + ivacaftor 250 mg q12h in Hepatic Impairment and Healthy, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-11-19.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
23
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study is designed to evaluate the pharmacokinetics (PK) and safety of multiple doses of lumacaftor in combination with ivacaftor in subjects with moderate hepatic impairment.

02

Conditions studied

  • Hepatic Impairment
  • Healthy

Keywords

  • pharmacokinetics, hepatic impairment
03

In context

Lead sponsor

Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.

Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Group A: Subjects with Moderate Hepatic Impairment

  • Male and female 18 to 65 years of age (inclusive)
  • Satisfy the criteria for moderate hepatic impairment defined as a total score of 7 to 9 (Child Pugh Class B) at the Screening Visit
  • Willing and able to comply with schedule visits, treatment, laboratory tests, and guidelines.

Group B: Healthy subjects

  • Male and female 18 to 65 years of age (inclusive)
  • Healthy subjects with no abnormalities identified by a detailed medical history, complete physical examination, including blood pressure and pulse rate measurement, standard 12-lead , and clinical laboratory tests
  • Willing and able to comply with schedule visits, treatment, laboratory tests, contraceptive guidelines and other study procedures

Exclusion criteria

Exclusion Criteria:

Group A: Subjects with Moderate Hepatic Impairment

  • History of any illness that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug(s) to the subject
  • Have fluctuating or rapidly deteriorating hepatic function by history or as indicated by significant variations in or worsening of clinical and/or laboratory signs of hepatic impairment within 6 months before the Screening Visit
  • Other causes of hepatic impairment not related to parenchymal disorder and/or disease of the liver
  • Severe hepatic encephalopathy
  • Type 1 diabetes mellitus or evidence of poorly controlled type 2 diabetes
  • Hepatocellular carcinoma, , /C
  • Significant renal dysfunction
  • Solid organ or bone marrow transplantation
  • History of regular alcohol consumption, drug abuse or regular smoking

Group B: Healthy subjects

  • History of any illness that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug(s) to the subject
  • History of regular alcohol consumption, drug abuse or regular smoking
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Group A

    Approximately 12 subjects (male and female) with moderate hepatic impairment

    Drug: lumacaftor 200 mg q12h + ivacaftor 250 mg q12h

  • Experimental
    Group B

    Approximately 12 healthy subjects (male and female)

    Drug: lumacaftor 200 mg q12h + ivacaftor 250 mg q12h

Interventions

  • Druglumacaftor 200 mg q12h + ivacaftor 250 mg q12h

    Drug page: Lumacaftor

06

What researchers measure

Primary outcomes

  1. Lumacaftor pharmacokinetic parameters, including Cmax, tmax, AUC, Vd, CL/F

    Time frame: 16 days

  2. Ivacaftor pharmacokinetic parameters, including Cmax, tmax, AUC, Vd, CL/F

    Time frame: 16 days

Secondary outcomes

  1. Lumacaftor metabolites pharmacokinetic parameters, including Cmax and AUC

    Time frame: 16 days

  2. Ivacaftor metabolites pharmacokinetic parameters including Cmax, tmax, AUC

    Time frame: 16 days

  3. Safety and tolerability as mentioned by adverse events, clinical laboratory values, standard electrocardiograms, Vital signs and pulse oximetry

    Time frame: 21 days

07

Study locations

2 sites
  • Praha, Czech Republic
  • Bratislava, Slovakia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2013
First posted
Jun 27, 2013
Start
Jun 2013
Primary completionActual
Nov 2013
CompletionActual
Nov 2013
Last update
Nov 19, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01888393
Responsible party
Sponsor
First posted
Jun 27, 2013
Start date
Jun 2013
Primary completion
Nov 2013
Completion
Nov 2013
Last update
Nov 19, 2013

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lumacaftor

Start the discussion